SC 13D/A 1 v021066_sc13da.txt ================================================================================ --------------------------- OMB APPROVAL --------------------------- OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response . . . 11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 --------------- SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* -------------- DepoMed, Inc. (Name of Issuer) Common Stock, no par value per share (Title of Class of Securities) 249908 10 4 (CUSIP Number) Andrew Beck Torys LLP 237 Park Avenue New York, New York 10017.3142 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) December 13, 2004 (Date of Event Which Requires Filing of Statement on Schedule 13D) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), checking the following box. |_| * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). ================================================================================ CUSIP No. 249908 10 4 Amendment No. 2 to Schedule 13D Page 2 of 21 Pages -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- (1) Name of Reporting Persons: I.R.S. Identification No. of Above Persons (entities only): MDS Capital Corp. -------------------------------------------------------------------------------- (2) Check the Appropriate Box if a Member of a Group (See Instructions): (a) |_| (b) |_| -------------------------------------------------------------------------------- (3) SEC Use Only: -------------------------------------------------------------------------------- (4) Source of Funds (See Instructions): AF -------------------------------------------------------------------------------- (5) Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e): |_| -------------------------------------------------------------------------------- (6) Citizenship or Place of Organization: Ontario, Canada -------------------------------------------------------------------------------- NUMBER OF (7) Sole Voting Power 0 SHARES ----------------------------------------------------- BENEFICIALLY (8) Shared Voting Power 1,941,423(1) OWNED ----------------------------------------------------- BY EACH (9) Sole Dispositive Power 0 REPORTING ----------------------------------------------------- PERSON WITH: (10) Shared Dispositive Power 1,941,423 (1) -------------------------------------------------------------------------------- (11) Aggregate Amount Beneficially Owned by Each Reporting Person: 1,941,423 (1) -------------------------------------------------------------------------------- (12) Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions): |_| -------------------------------------------------------------------------------- (13) Percent of Class Represented by Amount in Row (11): 4.78% (2) -------------------------------------------------------------------------------- (14) Type of Reporting Person (See Instructions): CO -------------------------------------------------------------------------------- (1) Includes 810,186 shares of Common Stock underlying the unexercised Warrants exercisable from and after July 21, 2003. (2) The percentage is based on 39,732,701 shares of Common Stock outstanding on May 6, 2005, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2005, together with the shares of Common Stock underlying the Purchasers' Warrants exercisable on July 21, 2003. CUSIP No. 249908 10 4 Amendment No. 2 to Schedule 13D Page 3 of 21 Pages -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- (1) Name of Reporting Persons: I.R.S. Identification No. of Above Persons (entities only): MDS Life Sciences Technology Fund II NC Limited Partnership -------------------------------------------------------------------------------- (2) Check the Appropriate Box if a Member of a Group (See Instructions): (a) |_| (b) |_| -------------------------------------------------------------------------------- (3) SEC Use Only: -------------------------------------------------------------------------------- (4) Source of Funds (See Instructions): WC -------------------------------------------------------------------------------- (5) Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e): |_| -------------------------------------------------------------------------------- (6) Citizenship or Place of Organization: Ontario, Canada -------------------------------------------------------------------------------- NUMBER OF (7) Sole Voting Power 0 SHARES ----------------------------------------------------- BENEFICIALLY (8) Shared Voting Power 881,708 (1) OWNED ----------------------------------------------------- BY EACH (9) Sole Dispositive Power 0 REPORTING ----------------------------------------------------- PERSON WITH: (10) Shared Dispositive Power 881,708 (1) -------------------------------------------------------------------------------- (11) Aggregate Amount Beneficially Owned by Each Reporting Person: 881,708 (1) -------------------------------------------------------------------------------- (12) Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions): |_| -------------------------------------------------------------------------------- (13) Percent of Class Represented by Amount in Row (11): 2.19% (2) -------------------------------------------------------------------------------- (14) Type of Reporting Person (See Instructions): PN -------------------------------------------------------------------------------- (1) Includes 364,584 shares of Common Stock underlying the unexercised Warrants exercisable from and after July 21, 2003. (2) The percentage is based on 39,732,701 shares of Common Stock outstanding on May 6, 2005, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2005, together with the shares of Common Stock underlying the Reporting Person's Warrants exercisable on July 21, 2003. CUSIP No. 249908 10 4 Amendment No. 2 to Schedule 13D Page 4 of 21 Pages -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- (1) Name of Reporting Persons: I.R.S. Identification No. of Above Persons (entities only): MDS Life Sciences Technology Fund II Quebec Limited Partnership -------------------------------------------------------------------------------- (2) Check the Appropriate Box if a Member of a Group (See Instructions): (a) |_| (b) |_| -------------------------------------------------------------------------------- (3) SEC Use Only: -------------------------------------------------------------------------------- (4) Source of Funds (See Instructions): WC -------------------------------------------------------------------------------- (5) Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e): |_| -------------------------------------------------------------------------------- (6) Citizenship or Place of Organization: Quebec, Canada -------------------------------------------------------------------------------- NUMBER OF (7) Sole Voting Power 0 SHARES ----------------------------------------------------- BENEFICIALLY (8) Shared Voting Power 283,145 (1) OWNED ----------------------------------------------------- BY EACH (9) Sole Dispositive Power 0 REPORTING ----------------------------------------------------- PERSON WITH: (10) Shared Dispositive Power 283,145 (1) ------------------------------------------------------------------------------- (11) Aggregate Amount Beneficially Owned by Each Reporting Person: 283,145 (1) -------------------------------------------------------------------------------- (12) Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions): |_| -------------------------------------------------------------------------------- (13) Percent of Class Represented by Amount in Row (11): 0.71% (2) -------------------------------------------------------------------------------- (14) Type of Reporting Person (See Instructions): PN -------------------------------------------------------------------------------- (1) Includes 121,528 shares of Common Stock underlying the unexercised Warrants exercisable from and after July 21, 2003. (2) The percentage is based on 39,732,701 shares of Common Stock outstanding on May 6, 2005, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2005, together with the shares of Common Stock underlying the Reporting Person's Warrants exercisable on July 21, 2003. CUSIP No. 249908 10 4 Amendment No. 2 to Schedule 13D Page 5 of 21 Pages -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- (1) Name of Reporting Persons: I.R.S. Identification No. of Above Persons (entities only): MLII Co-Investment Fund NC Limited Partnership -------------------------------------------------------------------------------- (2) Check the Appropriate Box if a Member of a Group (See Instructions): (a) |_| (b) |_| -------------------------------------------------------------------------------- (3) SEC Use Only: -------------------------------------------------------------------------------- (4) Source of Funds (See Instructions): WC -------------------------------------------------------------------------------- (5) Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e): |_| -------------------------------------------------------------------------------- (6) Citizenship or Place of Organization: Ontario, Canada -------------------------------------------------------------------------------- NUMBER OF (7) Sole Voting Power 0 SHARES ----------------------------------------------------- BENEFICIALLY (8) Shared Voting Power 388,285 (1) OWNED ----------------------------------------------------- BY EACH (9) Sole Dispositive Power 0 REPORTING ----------------------------------------------------- PERSON WITH: (10) Shared Dispositive Power 388,285 (1) -------------------------------------------------------------------------------- (11) Aggregate Amount Beneficially Owned by Each Reporting Person: 388,285 (1) -------------------------------------------------------------------------------- (12) Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions): |_| -------------------------------------------------------------------------------- (13) Percent of Class Represented by Amount in Row (11): 0.97% (2) -------------------------------------------------------------------------------- (14) Type of Reporting Person (See Instructions): PN -------------------------------------------------------------------------------- (1) Includes 162,037 shares of Common Stock underlying the unexercised Warrants exercisable from and after July 21, 2003. (2) The percentage is based on 39,732,701 shares of Common Stock outstanding on May 6, 2005, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2005, together with the shares of Common Stock underlying the Reporting Person's Warrants exercisable on July 21, 2003. CUSIP No. 249908 10 4 Amendment No. 2 to Schedule 13D Page 6 of 21 Pages -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- (1) Name of Reporting Persons: I.R.S. Identification No. of Above Persons (entities only): SC Biotechnology Development Fund LP -------------------------------------------------------------------------------- (2) Check the Appropriate Box if a Member of a Group (See Instructions): (a) |_| (b) |_| -------------------------------------------------------------------------------- (3) SEC Use Only: -------------------------------------------------------------------------------- (4) Source of Funds (See Instructions): WC -------------------------------------------------------------------------------- (5) Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e): |_| -------------------------------------------------------------------------------- (6) Citizenship or Place of Organization: Cayman Islands -------------------------------------------------------------------------------- NUMBER OF (7) Sole Voting Power 0 SHARES ----------------------------------------------------- BENEFICIALLY (8) Shared Voting Power 388,285 (1) OWNED ----------------------------------------------------- BY EACH (9) Sole Dispositive Power 0 REPORTING ----------------------------------------------------- PERSON WITH: (10) Shared Dispositive Power 388,285 (1) -------------------------------------------------------------------------------- (11) Aggregate Amount Beneficially Owned by Each Reporting Person: 388,285 (1) -------------------------------------------------------------------------------- (12) Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions): |_| -------------------------------------------------------------------------------- (13) Percent of Class Represented by Amount in Row (11): 0.97% (2) -------------------------------------------------------------------------------- (14) Type of Reporting Person (See Instructions): PN -------------------------------------------------------------------------------- (1) Includes 162,037 shares of Common Stock underlying the unexercised Warrants exercisable from and after July 21, 2003. (2) The percentage is based on 39,732,701 shares of Common Stock outstanding on May 6, 2005, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2005, together with the shares of Common Stock underlying the Reporting Person's Warrants exercisable on July 21, 2003. CUSIP No. 249908 10 4 Amendment No. 2 to Schedule 13D Page 7 of 21 Pages -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- (1) Name of Reporting Persons: I.R.S. Identification No. of Above Persons (entities only): MDS LSTF II (NCGP) Inc. -------------------------------------------------------------------------------- (2) Check the Appropriate Box if a Member of a Group (See Instructions): (a) |_| (b) |_| -------------------------------------------------------------------------------- (3) SEC Use Only: -------------------------------------------------------------------------------- (4) Source of Funds (See Instructions): AF -------------------------------------------------------------------------------- (5) Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e): |_| -------------------------------------------------------------------------------- (6) Citizenship or Place of Organization: Ontario, Canada -------------------------------------------------------------------------------- NUMBER OF (7) Sole Voting Power 0 SHARES ------------------------------------------------------ BENEFICIALLY (8) Shared Voting Power 881,708 (1) OWNED ------------------------------------------------------ BY EACH (9) Sole Dispositive Power 0 REPORTING ------------------------------------------------------ PERSON WITH: (10) Shared Dispositive Power 881,708 (1) -------------------------------------------------------------------------------- (11) Aggregate Amount Beneficially Owned by Each Reporting Person: 881,708 (1) -------------------------------------------------------------------------------- (12) Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions): [ ] -------------------------------------------------------------------------------- (13) Percent of Class Represented by Amount in Row (11): 2.19%(2) -------------------------------------------------------------------------------- (14) Type of Reporting Person (See Instructions): CO -------------------------------------------------------------------------------- (1) Includes 364,584 shares of Common Stock underlying the unexercised Warrants exercisable from and after July 21, 2003. (2) The percentage is based on 39,732,701 shares of Common Stock outstanding on May 6, 2005, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2005, together with the shares of Common Stock underlying the Reporting Person's Warrants exercisable on July 21, 2003. CUSIP No. 249908 10 4 Amendment No. 2 to Schedule 13D Page 8 of 21 Pages -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- (1) Name of Reporting Persons: I.R.S. Identification No. of Above Persons (entities only): MDS LSTF II (QGP) Inc. -------------------------------------------------------------------------------- (2) Check the Appropriate Box if a Member of a Group (See Instructions): (a) |_| (b) |_| -------------------------------------------------------------------------------- (3) SEC Use Only: -------------------------------------------------------------------------------- (4) Source of Funds (See Instructions): AF -------------------------------------------------------------------------------- (5) Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e): |_| -------------------------------------------------------------------------------- (6) Citizenship or Place of Organization: Quebec, Canada -------------------------------------------------------------------------------- NUMBER OF (7) Sole Voting Power 0 SHARES ----------------------------------------------------- BENEFICIALLY (8) Shared Voting Power 283,145 (1) OWNED ----------------------------------------------------- BY EACH (9) Sole Dispositive Power 0 REPORTING ----------------------------------------------------- PERSON WITH: (10) Shared Dispositive Power 283,145 (1) -------------------------------------------------------------------------------- (11) Aggregate Amount Beneficially Owned by Each Reporting Person: 283,145 (1) -------------------------------------------------------------------------------- (12) Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions): |_| -------------------------------------------------------------------------------- (13) Percent of Class Represented by Amount in Row (11): 0.71% (2) -------------------------------------------------------------------------------- (14) Type of Reporting Person (See Instructions): CO -------------------------------------------------------------------------------- (1) Includes 121,528 shares of Common Stock underlying the unexercised Warrants exercisable from and after July 21, 2003. (2) The percentage is based on 39,732,701 shares of Common Stock outstanding on May 6, 2005, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2005, together with the shares of Common Stock underlying the Reporting Person's Warrants exercisable on July 21, 2003. CUSIP No. 249908 10 4 Amendment No. 2 to Schedule 13D Page 9 of 21 Pages -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- (1) Name of Reporting Persons: I.R.S. Identification No. of Above Persons (entities only): MLII (NCGP) Inc. -------------------------------------------------------------------------------- (2) Check the Appropriate Box if a Member of a Group (See Instructions): (a) |_| (b) |_| -------------------------------------------------------------------------------- (3) SEC Use Only: -------------------------------------------------------------------------------- (4) Source of Funds (See Instructions): AF -------------------------------------------------------------------------------- (5) Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e): |_| -------------------------------------------------------------------------------- (6) Citizenship or Place of Organization: Ontario, Canada -------------------------------------------------------------------------------- NUMBER OF (7) Sole Voting Power 0 SHARES ----------------------------------------------------- BENEFICIALLY (8) Shared Voting Power 388,285 (1) OWNED ----------------------------------------------------- BY EACH (9) Sole Dispositive Power 0 REPORTING ----------------------------------------------------- PERSON WITH: (10) Shared Dispositive Power 388,285 (1) -------------------------------------------------------------------------------- (11) Aggregate Amount Beneficially Owned by Each Reporting Person: 388,285 (1) -------------------------------------------------------------------------------- (12) Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions): |_| -------------------------------------------------------------------------------- (13) Percent of Class Represented by Amount in Row (11): 0.97% (2) -------------------------------------------------------------------------------- (14) Type of Reporting Person (See Instructions): CO -------------------------------------------------------------------------------- (1) Includes 162,037 shares of Common Stock underlying the unexercised Warrants exercisable from and after July 21, 2003. (2) The percentage is based on 39,732,701 shares of Common Stock outstanding on May 6, 2005, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2005, together with the shares of Common Stock underlying the Reporting Person's Warrants exercisable on July 21, 2003. CUSIP No. 249908 10 4 Amendment No. 2 to Schedule 13D Page 10 of 21 Pages -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- (1) Name of Reporting Persons: I.R.S. Identification No. of Above Persons (entities only): SC (GP) Inc. -------------------------------------------------------------------------------- (2) Check the Appropriate Box if a Member of a Group (See Instructions): (a) |_| (b) |_| -------------------------------------------------------------------------------- (3) SEC Use Only: -------------------------------------------------------------------------------- (4) Source of Funds (See Instructions): AF -------------------------------------------------------------------------------- (5) Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e): |_| -------------------------------------------------------------------------------- (6) Citizenship or Place of Organization: Cayman Islands -------------------------------------------------------------------------------- NUMBER OF (7) Sole Voting Power 0 SHARES ----------------------------------------------------- BENEFICIALLY (8) Shared Voting Power 388,285 (1) OWNED ----------------------------------------------------- BY EACH (9) Sole Dispositive Power 0 REPORTING ----------------------------------------------------- PERSON WITH: (10) Shared Dispositive Power 388,285 (1) -------------------------------------------------------------------------------- (11) Aggregate Amount Beneficially Owned by Each Reporting Person: 388,285 (1) -------------------------------------------------------------------------------- (12) Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions): [ ] -------------------------------------------------------------------------------- (13) Percent of Class Represented by Amount in Row (11): 0.97% (2) -------------------------------------------------------------------------------- (14) Type of Reporting Person (See Instructions): CO -------------------------------------------------------------------------------- (1) Includes 162,037 shares of Common Stock underlying the unexercised Warrants exercisable from and after July 21, 2003. (2) The percentage is based on 39,732,701 shares of Common Stock outstanding on May 6, 2005, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2005, together with the shares of Common Stock underlying the Reporting Person's Warrants exercisable on July 21, 2003. CUSIP No. 249908 10 4 Amendment No. 2 to Schedule 13D Page 11 of 21 Pages -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- (1) Name of Reporting Persons: I.R.S. Identification No. of Above Persons (entities only): MDS Capital Management Corp. -------------------------------------------------------------------------------- (2) Check the Appropriate Box if a Member of a Group (See Instructions): (a) |_| (b) |_| -------------------------------------------------------------------------------- (3) SEC Use Only: -------------------------------------------------------------------------------- (4) Source of Funds (See Instructions): AF -------------------------------------------------------------------------------- (5) Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e): [ ] -------------------------------------------------------------------------------- (6) Citizenship or Place of Organization: Ontario, Canada -------------------------------------------------------------------------------- NUMBER OF (7) Sole Voting Power 0 SHARES ----------------------------------------------------- BENEFICIALLY (8) Shared Voting Power 881,708 (1) OWNED ----------------------------------------------------- BY EACH (9) Sole Dispositive Power 0 REPORTING ----------------------------------------------------- PERSON WITH: (10) Shared Dispositive Power 881,708 (1) -------------------------------------------------------------------------------- (11) Aggregate Amount Beneficially Owned by Each Reporting Person: 881,708 (1) -------------------------------------------------------------------------------- (12) Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions): |_| -------------------------------------------------------------------------------- (13) Percent of Class Represented by Amount in Row (11): 2.19% (2) -------------------------------------------------------------------------------- (14) Type of Reporting Person (See Instructions): CO -------------------------------------------------------------------------------- (1) Includes 364,584 shares of Common Stock underlying the unexercised Warrants exercisable from and after July 21, 2003. (2) The percentage is based on 39,732,701 shares of Common Stock outstanding on May 6, 2005, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2005, together with the shares of Common Stock underlying Life NC's Warrants exercisable on July 21, 2003. CUSIP No. 249908 10 4 Amendment No. 2 to Schedule 13D Page 12 of 21 Pages -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- (1) Name of Reporting Persons: I.R.S. Identification No. of Above Persons (entities only): Michael Callaghan -------------------------------------------------------------------------------- (2) Check the Appropriate Box if a Member of a Group (See Instructions): (a) |_| (b) |_| -------------------------------------------------------------------------------- (3) SEC Use Only: -------------------------------------------------------------------------------- (4) Source of Funds (See Instructions): AF -------------------------------------------------------------------------------- (5) Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e): |_| -------------------------------------------------------------------------------- (6) Citizenship or Place of Organization: Canada -------------------------------------------------------------------------------- NUMBER OF (7) Sole Voting Power 18,750(1) SHARES ----------------------------------------------------- BENEFICIALLY (8) Shared Voting Power 0 OWNED ----------------------------------------------------- BY EACH (9) Sole Dispositive Power 18,750(1) REPORTING ----------------------------------------------------- PERSON WITH: (10) Shared Dispositive Power -------------------------------------------------------------------------------- (11) Aggregate Amount Beneficially Owned by Each Reporting Person: 18,750 (1) -------------------------------------------------------------------------------- (12) Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions): |_| -------------------------------------------------------------------------------- (13) Percent of Class Represented by Amount in Row (11): 0.04% (2) -------------------------------------------------------------------------------- (14) Type of Reporting Person (See Instructions): IN -------------------------------------------------------------------------------- (1) 18,750 options exercisable into 18,750 shares of Common Stock. (2) The percentage is based on 39,732,701 shares of Common Stock outstanding on May 6, 2005, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2005, together with the shares of Common Stock underlying the Options. CUSIP No. 249908 10 4 Amendment No. 2 to Schedule 13D Page 13 of 21 Pages -------------------------------------------------------------------------------- This Amendment No. 2 to Schedule 13D (this "Amendment No. 2") amends and supplements the Statement on Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on May 1, 2003 (the "Schedule 13D") and amendment filed on April 16, 2004, which relates to the common stock, no par value per share (the "Common Stock") of DepoMed, Inc., a California corporation (the "Issuer"). Capitalized terms used herein and not otherwise defined in this Amendment No. 2 shall have the meanings set forth in the Schedule 13D. This Amendment No. 2 is being filed by MDS Capital Corp., a corporation incorporated under the laws of Ontario, Canada ("MDS Capital"), MDS Life Sciences Technology Fund II NC Limited Partnership, an Ontario limited partnership ("Life NC"), MDS Life Sciences Technology Fund II Quebec Limited Partnership, a Quebec limited partnership ("Life Quebec"), MLII Co-Investment Fund NC Limited Partnership, an Ontario limited partnership ("MLII NC"), SC Biotechnology Development Fund LP, a Cayman Islands limited partnership ("SC Biotech"), MDS LSTF II (NCGP) Inc., an Ontario corporation ("NCGP"), MDS LSTF II (QGP) Inc., a Quebec corporation ("QGP"), MLII (NCGP) Inc., an Ontario corporation ("MLII GP"), SC (GP) Inc., a Cayman Islands corporation ("SCGP"), MDS Capital Management Corp. (formerly MDS Health Ventures Management Inc.), an Ontario corporation ("MDS Management") and Michael Callaghan, Canadian individual residing in the United States (collectively, "Reporting Persons") pursuant to their Joint Filing Agreement (incorporated by reference to Exhibit 3 to the Schedule 13D filed with the SEC on May 1, 2003). ITEM 2. IDENTITY AND BACKGROUND Item 2 is hereby amended to add the following information: Appendix A attached hereto and incorporated herein by reference sets forth, with respect to each executive officer and director of MDS Capital and each executive officer and director of NCGP, QGP, MLII GP, SCGP and MDS Management the following information: (a) name; (b) residence or business address; (c) present principal occupation or employment and the name, principal business and address of any corporation or other organization in which such employment is conducted; and (d) citizenship of such person. Life Quebec's principal business is to invest in companies in the health care and life sciences sectors. The principal business address of Life Quebec is 2000 Peel Street, Suite 560, Montreal, Quebec, H3A 2W5. Mr. Callaghan serves as Sr. Vice-President of MDS Capital. Mr. Callaghan's principal office is at MDS Capital (U.S.A.) Corp. located at 435 Tasso Street, Suite 315, Palo Alto, CA 94301-1552. QGP's principal business is acting as the general partner of Life Quebec. The principal business address of QGP is 2000 Peel Street, Suite 560, Montreal, Quebec, H3A 2W5. None of the Reporting Persons or the individuals listed in Appendix A has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years preceding the date of this Amendment No. 2. CUSIP No. 249908 10 4 Amendment No. 2 to Schedule 13D Page 14 of 21 Pages -------------------------------------------------------------------------------- None of the Reporting Persons or the individuals listed in Appendix A has been party to any civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws, or finding any violation with respect to such laws during the last five years preceding the date of this Amendment No. 2. ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION Item 3 is hereby amended to add the following information: Between May 21, 2004 and June 22, 2005, 1,050,175 shares of Common Stock were sold over the NASDAQ National Market. The following dispositions of Common Stock occurred: Life NC disposed of 465,355 shares of Common Stock; Life Quebec disposed of 164,752 shares of Common Stock; MLII NC disposed of 210,034 shares of Common Stock; and SC Biotech disposed of 210,034 shares of Common Stock, all at prices ranging from $4.26 per share to $7.80 per share. As a result of such sales, the total aggregate beneficial ownership of the Reporting Persons was reduced by 1,050,175 shares of Common Stock. ITEM 4. PURPOSE OF THE TRANSACTION The first paragraph of Item 4 is hereby amended and restated in its entirety: The Securities have been acquired for the purpose of making an investment in the Issuer and not with the present intention of changing or affecting control of the Issuer or its business or affecting any other transaction listed in Item 4 of Schedule 13D. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER Item 5 is hereby amended and restated in its entirety: (a) and (b) As a result of certain relationships, the following Reporting Persons may be deemed to directly and/or indirectly beneficially own the following shares of Common Stock and Warrants respectively: MDS Capital 1,131,237 and 810,186 (4.78%); Life NC 517,124 and 364,584 (2.19%); Life Quebec 161,617 and 121,528 (0.71%); MLII NC 226,248 and 162,037 (0.97%); SC Biotech 226,248 and 162,037 (0.97%); NCGP 517,124 and 364,584 (2.19%); QGP 161,617 and 121,528 (0.71%); MLII GP 226,248 and 162,037 (0.97%); SCGP 226,248 and 162,037 (0.97%); and MDS Management 517,124 and 364,584 (2.19%). The percentage held is based on the number of shares of Common Stock reported to be outstanding as of May 6, 2005, in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2005, as filed with the SEC on May 10, 2005, together with the shares underlying the Purchaser's Warrants. Michael Callaghan may be deemed to directly and/or indirectly beneficially own an additional 18,750 shares of Common Stock underlying stock options granted to him when he was a director of the Issuer (the "Options"). Each Reporting Person disclaims beneficial ownership of any Securities beneficially owned by any other Reporting Person. Due to their relationship with one another, the Reporting Persons may be deemed to constitute a "group" under Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Act"), with respect to their beneficial ownership of the shares of Common Stock, Warrants and Options. The Reporting Persons, however, expressly disclaim such status and declare that the filings of this Amendment No. 2, the Schedule 13D, and Amendment No. 1 are not and should not be deemed admissions that any Reporting Person, for purposes of Section 13(d) of the Act or otherwise, is the beneficial owner of the shares of Common Stock or Warrants held by any other Reporting Person. CUSIP No. 249908 10 4 Amendment No. 2 to Schedule 13D Page 15 of 21 Pages -------------------------------------------------------------------------------- If the Reporting Persons listed below are deemed to beneficially own the Securities of the certain other Reporting Persons, then:
Number of Shares With Aggregate Percentage Sole Voting and Number of Shares With Shared Number of of Class Reporting Dispositive Voting Shares Beneficially Persons Power and Dispositive Power Beneficially Owned Owned ------------------- --------------------- ---------------------------- ------------------ ------------- Underlying Common Underlying Options Stock Warrants (1) MDS Capital 0 1,131,237 810,186 1,941,423 4.78% Life NC, NCGP and MDS Management 0 517,124 364,584 881,708 2.19% Life Quebec and QGP 0 161,617 121,528 283,145 0.71% MLII NC and MLII GP 0 226,248 162,037 388,285 0.97% SC Biotech and SCGP 0 226,248 162,037 388,285 0.97% Michael Callaghan 18,750 0 18,750 0.04%
(1) Warrants are exercisable for five years commencing July 21, 2003. (c) Other than as reported in this Amendment No. 2, none of the Reporting Persons has effected any transactions involving the Common Stock, the Warrants or the Options in the 60 days prior to the date of this Amendment No. 2. (d) No other persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Securities. The Reporting Persons cease to be the beneficial owner of more than five percent of the Common Stock on June 21, 2005 CUSIP No. 249908 10 4 Amendment No. 2 to Schedule 13D Page 16 of 21 Pages -------------------------------------------------------------------------------- ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER Item 6 is hereby deleted in its entirety. SIGNATURE After reasonable inquiry and to the best of the undersigned's knowledge and belief, each of the undersigned certifies that the information set forth in this Amendment No. 2 is true, complete and correct. Dated as of June 23, 2005. MDS Capital Corp. By: /s/Gregory Gubitz /s/Graysanne Bedell ------------------------------------------------------------ Name: Gregory Gubitz Graysanne Bedell Title: Chief Operating Vice-President - Legal and Secretary Officer MDS Life Sciences Technology Fund II NC Limited Partnership By: MDS LSTF II (NCGP) Inc., its General Partner By: /s/Gregory Gubitz /s/Graysanne Bedell ------------------------------------------------------------ Name: Gregory Gubitz Graysanne Bedell Title: Chief Operating Vice-President and Secretary Officer and Director MDS Life Sciences Technology Fund II Quebec Limited Partnership By: MDS LSTF II (QGP) Inc., its General Partner By: /s/Gregory Gubitz /s/Graysanne Bedell ------------------------------------------------------------ Name: Gregory Gubitz Graysanne Bedell Title: Chief Operating Vice-President and Secretary Officer MLII Co-Investment Fund NC Limited Partnership By: MLII (NCGP) Inc., its General Partner By: /s/Gregory Gubitz /s/Graysanne Bedell ------------------------------------------------------------ Name: Gregory Gubitz Graysanne Bedell Title: Chief Operating Vice-President & Secretary Officer and Director CUSIP No. 249908 10 4 Amendment No. 2 to Schedule 13D Page 17 of 21 Pages -------------------------------------------------------------------------------- SC Biotechnology Development Fund LP By: SC (GP) Inc., its General Partner By: /s/ Alan Milgate /s/ Charlette Clarke ------------------------------------------------------------ Name: Alan Milgate Charlette Clarke Title: Directors of Cardinal Investments Limited, Director of SC (GP) Inc. MDS LSTF II (NCGP) Inc. By: /s/Gregory Gubitz /s/Graysanne Bedell ------------------------------------------------------------ Name: Gregory Gubitz Graysanne Bedell Title: Chief Operating Vice-President & Secretary Officer and Director MDS LSTF II (QGP) Inc. By: /s/Gregory Gubitz /s/Graysanne Bedell ------------------------------------------------------------ Name: Gregory Gubitz Graysanne Bedell Title: Chief Operating Vice-President & Secretary Officer & Director MLII (NCGP) Inc. By: /s/Gregory Gubitz /s/Graysanne Bedell ------------------------------------------------------------ Name: Gregory Gubitz Graysanne Bedell Title: Chief Operating Vice-President & Secretary Officer and Director SC (GP) Inc. By: /s/ Alan Milgate /s/ Charlette Clarke ------------------------------------------------------------ Name: Alan Milgate Charlette Clarke Title: Directors of Cardinal Investments Limited, Director of SC (GP) Inc. MDS Capital Management Corp. By: /s/ Michael Callaghan /s/ Richard Lockie ------------------------------------------------------------ Name: Michael Callaghan Richard Lockie Title: Sr. Vice-President Sr. Vice-President /s/ Michael Callaghan -------------------------------------------------------------------- Michael Callaghan CUSIP No. 249908 10 4 Amendment No. 2 to Schedule 13D Page 18 of 21 Pages -------------------------------------------------------------------------------- APPENDIX A MDS Capital Corp.: Sole Shareholder of the General Partners of the Purchasers ----------------------------------------------------------------------------- Unless otherwise noted below, each of the listed individuals is a citizen of Canada and has as his/her business address 100 International Boulevard, Toronto, Ontario M9W 6J6. Unless otherwise noted, each of the listed persons' position with MDS Capital is also his/her principal occupation.
NAME/PLACE of POSITION with PRINCIPAL PRINCIPAL BUSINESS CITIZENSHIP MDS CAPITAL OCCUPATION ADDRESS ----------- ----------- ---------- ------- John A. Rogers Director/Executive Chairman Executive Chairman, President and Chief Executive Officer of MDS Capital Michael Burns Director Chairman, The Sentinel Group 1450 Creekside Drive, Suite 100 Vancouver, B.C. V6J5B3 Peter de Auer Director President, Cluster Asset 130 Bloor Street West, Suite 600 Management Inc. Toronto, Ontario M5S 1N5 James Garner Director Executive Vice-President & Chief Financial Officer, MDS Inc. Richard Johnston Director Independent Consultant 1325 Winterberry Drive Burlington, Ontario L7P 4S7 James Osborne Director President, Westgate Capital 167 Lombard Ave., Suite 808 Corp. Winnipeg, Manitoba R3B 0V3 Andrew McIntyre Director Manager, Private Marketing, 1 Queen St. E., Suite 2700, Canada Pension Plan Investment Toronto, Ontario M5C 2W5 Board Anthony Pullen Director Managing Director, Loewen, 55 Avenue Road, Suite 2250 Ondaajtje, McCutcheon Limited Toronto, Ontario M5R 3L2 Michael Callaghan Sr. Vice-President 435 Tasso Street, Suite 315 Palo Alto, CA 94301-1552 Darrell Elliot Sr. Vice-President Gregory Gubitz Chief Operating Officer Richard Lockie Sr. Vice-President Jean-Christophe Sr. Vice-President 2000 Peel St., Suite 506 Renondin - France Montreal, Quebec H3A 2W5 Brian Underdown Sr. Vice-President Robert Allan Vice-President Graysanne Bedell Vice-President Legal & Secretary Stephen Cummings Vice-President Finance Gerald Brunk - United Vice-President 245 First St., Suite 1800 States Cambridge, MA 02142 Anthony Flynn Sr. Vice-President & Chief Financial Officer Jason Gross - United Vice-President States Vincent Lum Vice-President 1095 W. Pender St., Suite 1120 Vancouver, B.C. V6E 2M6 Malcolm Kendall - United Vice-President 1095 W. Pender St., Suite 1120 States Vancouver, B.C. V6E 2M6 Benjamin Rovinski Vice-President Anthony Natale United Vice-President 245 First St., Suite 1800 States Cambridge, MA 02142 Nandini Tandon - India Vice-President 187 Easy Street Mountain View, CA 94043 Hakan Telenius Vice-President 1095 W. Pender St., Suite 1120 Vancouver, B.C. V6E 2M6
CUSIP No. 249908 10 4 Amendment No. 2 to Schedule 13D Page 19 of 21 Pages -------------------------------------------------------------------------------- MDS Capital Management Corp.: Manager of Life NC ------------------------------------------------ Unless otherwise noted below, each of the listed persons is a citizen of Canada and has as his/her business address 100 International Boulevard, Toronto, Ontario M9W 6J6.
POSITION with PRINCIPAL NAME MDS Management OCCUPATION Brian Underdown Sr. Vice-President Sr. Vice-President of MDS Capital Stephen Cummings Vice-President, Finance Vice-President - Finance of MDS Capital Graysanne Bedell Vice-President, Legal, & Secretary Vice-President, Legal, & Secretary of MDS Capital Gregory Gubitz Director & Chief Operating Officer Chief Operating Officer of MDS Capital Michael Callaghan Sr. Vice President/ Authorized Sr. Vice-President of MDS Capital Trading Officer Darrell Elliott Sr. Vice-President Sr. Vice-President of MDS Capital Jean-Christophe Renondin - France Sr. Vice-President Sr. Vice-President of MDS Capital Richard Lockie Sr. Vice President/Authorized Sr. Vice-President of MDS Capital Trading Officer Anthony Flynn Sr. Vice-President/Chief Sr. Vice-President & Chief Financial Officer of MDS Financial Officer Capital
MDS LSTF II (NCGP) Inc.: General Partner of Life NC --------------------------------------------------- Unless otherwise noted below, each of the listed persons is a citizen of Canada and has as his/her business address 100 International Boulevard, Toronto, Ontario M9W 6J6.
NAME/ PLACE of POSITION with PRINCIPAL PRINCIPAL BUSINESS CITIZENSHIP MDS LSTF II (NCGP) OCCUPATION ADDRESS ----------- ------------------ ---------- ------- Michael Mueller Director/President President & Chief Executive Officer of MDS Capital Gregory Gubitz Director/Chief Operating Sr. Vice-President of MDS Capital Officer Graysanne Bedell Secretary & Vice-President Vice-President - Legal of MDS Capital Michael Callaghan Vice-President Sr. Vice-President of MDS Capital 435 Tasso Street, Suite 315 Palo Alto, CA 94301-1552 Darrell Elliot Vice-President Sr. Vice-President of MDS Capital Richard Lockie Vice-President Sr. Vice-President of MDS Capital Jean-Christophe Vice-President Sr. Vice-President of MDS Capital 2000 Peel St., Suite 560 Renondin - France Montreal, Quebec H3A 2W5 Stephen Cummings Vice-President, Finance Vice-President, Finance, of MDS Capital Anthony Flynn Vice-President/Chief Sr. Vice-President & Chief Financial Financial Officer Officer of MDS Capital Brian Underdown Vice-President Sr. Vice-President of MDS Capital
CUSIP No. 249908 10 4 Amendment No. 2 to Schedule 13D Page 20 of 21 Pages -------------------------------------------------------------------------------- MDS LSTF II (QGP) Inc.: General Partner of Life Quebec ------------------------------------------------------- Unless otherwise noted below, each of the listed persons is a citizen of Canada and has as his/her business address 2000 Peel St., Suite 560, Montreal, Quebec H3A 2W5.
NAME/ PLACE of POSITION with PRINCIPAL PRINCIPAL BUSINESS CITIZENSHIP MDS LSTF II (NCGP) OCCUPATION ADDRESS ----------- ------------------ ---------- ------- Bernard Coupal Director President, Societe en Commandite T2C2/BIO 1550 Metcalf St., Suite 502 Montreal, Quebec H3A 1X6 Maurice Forget Director Partner, Fasken Martineau DuMoulin LLP 800 Place Victoria, Montreal, Quebec H3B 4S9 Murray Ducharme Director Vice-President, Pharmacokinetis & 2350 Cohen Pharmacodynamics, MDS Pharma Services St-Laurent, Quebec Division, MDS (Canada) Inc. H4R 2T6 Jean Page Director Managing Director, National Bank Financial 1155 Metcalfe St. 5th Floor Inc. Montreal, Quebec H3B 4S9 Graysanne Bedell Secretary/Vice-President Vice-President - Legal and Secretary of MDS 100 International Boulevard Capital Toronto, Ontario M9W 6J6 Gregory Gubitz Director/Chief Operating Chief Operating Officer of MDS Capital 100 International Boulevard Officer Toronto, Ontario M9W 6J6 Jean-Christophe Vice-President Sr. Vice-President of MDS Capital Renondin - France Michael Callaghan Vice-President Sr. Vice-President of MDS Capital 435 Tasso Street, Suite 315 Palo Alto, CA 94301-1552 Richard Lockie Vice-President Sr. Vice-President of MDS Capital 100 International Boulevard Toronto, Ontario M9W 6J6 Darrell Elliott Vice-President Sr. Vice-President of MDS Capital 1095 West Pender Street, Suite 1120, Vancouver, British Columbia V6E 2M6 Brian Underdown Vice-President Sr. Vice-President of MDS Capital 100 International Boulevard Toronto, Ontario M9W 6J6 Anthony Flynn Vice-President & Chief Sr. Vice-President & Chief Financial Officer 100 International Boulevard Financial Officer of MDS Capital Toronto, Ontario M9W 6J6 Stephen Cummings Vice-President, Finance Vice-President, Finance, of MDS Capital 100 International Boulevard Toronto, Ontario M9W 6J6
MLII (NCGP) Inc: General Partner of MLII NC -------------------------------------------- Unless otherwise noted below, each of the listed persons is a citizen of Canada and has as his/her business address 100 International Boulevard, Toronto, Ontario M9W 6J6.
NAME/PLACE of POSITION with PRINCIPAL PRINCIPAL BUSINESS CITIZENSHIP MLII (NCGP) OCCUPATION ADDRESS ----------- ----------- ---------- ------- Gregory Gubitz Director/Chief Chief Operating Officer of MDS Capital Operating Officer Graysanne Bedell Secretary/Vice President Vice-President - Legal and Secretary of MDS Capital Michael Callaghan Vice-President Sr. Vice-President of MDS Capital 435 Tasso Street, Suite 315 Palo Alto, CA 94301-1552 Darrell Elliott Vice-President Sr. Vice-President of MDS Capital 1095 W. Pender St., Suite 1120 Vancouver, B.C. V6E 2M6 Richard Lockie Vice-President Sr. Vice-President of MDS Capital Jean-Christophe Renondin Vice-President Sr. Vice-President of MDS Capital 2000 Peel St., Suite 560 - France Montreal, Quebec H3A 2W6 Stephen Cummings Vice President, Finance Vice-President, Finance, of MDS Capital Anthony Flynn Vice President/Chief Sr. Vice-President and Chief Financial Financial Officer Officer of MDS Capital Brian Underdown Vice President Sr. Vice-President of MDS Capital
CUSIP No. 249908 10 4 Amendment No. 2 to Schedule 13D Page 21 of 21 Pages -------------------------------------------------------------------------------- SC (GP) Inc.: General Partner of SC Biotech ------------------------------------------- Unless otherwise noted below, each of the listed persons is a citizen of Canada and has as his/her business address One Capital Place, P.O. Box 897, GT Grand Cayman, Cayman Islands. POSITION with PRINCIPAL NAME SC (GP) OCCUPATION ---- ------- ---------- Cardinal Investments Limited Director N/A Woodbourne Associates (Cayman) Secretary N/A Limited Cardinal Investments Limited: Sole Director of SC (GP) Inc. ----------------------------------------------------------- Unless otherwise noted below, each of the listed persons' principal occupation is a Chartered Accountant and has as his/her business address P.O. Box 1787 GT, Grand Cayman, Cayman Islands, except Woodburne Associates which has as a principal business address P.O. Box 897, GT Grand Cayman, Cayman Islands.
PLACE of POSITION with PRINCIPAL NAME CITIZENSHIP Cardinal Investments OCCUPATION ---- ----------- -------------------- ---------- Alan Milgate Canada Director Alison Hill Britain Director Chartered Secretary Charlette Clarke Cayman Islands Director Patricia Trotter Cayman Islands Director Peter Anderson Britain Director Richard Douglas Britain/Cayman Islands Director Tamara Corbin Cayman Islands Director William Walmsley Britain/Cayman Islands Director John Ackerley Britain Director Woodbourne Associates Cayman Company Secretary Nominee Company (Cayman) Limited
Woodbourne Associates (Cayman) Limited: Sole Officer of SC (GP), Inc. --------------------------------------------------------------------- Unless otherwise noted below, each of the listed persons' principal occupation is a chartered accountant and has as his/her business address P.O. Box 1787 GT, Grand Cayman, Cayman Islands.
PLACE of POSITION with PRINCIPAL NAME CITIZENSHIP Cardinal Investments OCCUPATION Alan Milgate Canada Director Alison Hill Britain Director Charlette Clarke Cayman Islands Director Patricia Trotter Cayman Islands Director Peter Anderson Britain Director Richard Douglas Britain/Cayman Islands Director Tamara Corbin Cayman Islands Director William Walmsley Britain Director & Secretary Secretary John Ackerley Britain Director